W
WAVEMAN · COMPANY
AMRX · Amneal Pharmaceuticals, Inc.
> Ask across nine datasets ⌘K
LIVE
TEAM-2.62% 13F +440META+1.00% 13F +2,694RCG+0.35% CLUSTERUTHR-0.54% 13F +425CRWV+5.68% 13F +694CRM-1.97% 13F +1,019CVNA+1.58% 13F +795TPL-1.11% 13F +444NET-1.96% 13F +711MSTR-1.39% 13F +527DELL+1.50% 13F +1,204CRWD-0.87% 13F +1,383ANET+1.22% 13F +1,324COIN-4.18% 13F +475TEAM-2.62% 13F +440META+1.00% 13F +2,694RCG+0.35% CLUSTERUTHR-0.54% 13F +425CRWV+5.68% 13F +694CRM-1.97% 13F +1,019CVNA+1.58% 13F +795TPL-1.11% 13F +444NET-1.96% 13F +711MSTR-1.39% 13F +527DELL+1.50% 13F +1,204CRWD-0.87% 13F +1,383ANET+1.22% 13F +1,324COIN-4.18% 13F +475
← ALL COMPANIES

AMRX

Amneal Pharmaceuticals, Inc.
PHARMA & BIOTECH · PHARMACEUTICAL PREPARATIONS · CIK 0001723128
FORM 144 · 4☆ WATCH
INSIDER NET · 180D
-$7.7M
open-market buys minus sells, Form 4 codes P and S
INSIDER BUYERS · 180D
0
CONGRESS BUYERS · 1Y
0
FUNDS ADDED · QTR
189
13F, latest reported quarter
REVENUE GROWTH
+8.0%
XBRL, annual
NET MARGIN
2.4%
CONVERSIONS · 180D
9
codes C/M, not in net · $2.9M priced
SEVEN FACTS, RANKED AGAINST THE SECTOR · RANK IS NOT A FORECAST
INSIDERS
net -$7.7M over 180 days
-$7.2M over 90 days
below 82% of Pharma & Biotech
CONGRESS
no member of Congress has reported trading it
FUNDS
189 funds added or opened last quarter
more than 85% of Pharma & Biotech
REVENUE
+8.0% year over year
more than 58% of Pharma & Biotech
MARGIN
2.4% net margin
more than 70% of Pharma & Biotech
BUYBACKS
no share repurchases reported
SHORT
2.6% of shares outstanding short · 4.6 days to cover · settled 2026-07-31
below 59% of Pharma & Biotech
THE SITUATION · EVERY LINE IS ONE RULE OVER ONE DATASET
Insiders are net sellers: -$7.7M across 4 people in 180 days.
189 funds added or opened positions in the latest 13F quarter, of 312 holders.
The year, with the filings on it
Total return indexed to 100 over the last 12 months · every marker is a federal filing, placed at its date — hover any marker for the detail
TOTAL 12M RETURN +82.0%
+82.0%12M
-0%+33%+66%+99%2025-092025-102025-122026-032026-052026-072026-09 2026-08-12 · Daly Jason B. sold $3.7M2026-08-12 · Shah Nikita sold $2.6M2025-11-12 · Shah Nikita sold $1.6M2026-08-13 · Kiely John sold $882.0K2025-11-17 · Nark Ted C sold $586.0K2026-05-11 · Autor Deborah M. sold $450.6K2026-08-11 · Daly Jason B. sold $117.1K2026-08-13 · JOHN KIELY filed to sell $879.7K2026-08-12 · JASON DALY filed to sell $3.6M2026-08-12 · NIKITA SHAH filed to sell $2.6M2026-08-11 · BUCHI J KEVIN filed to sell $2.9M
INSIDER SELLFORM 144
INDEXED RETURN, DIVIDEND-ADJUSTED — NOT A PRICE CHART · LARGE TRADES DRAWN FIRST WHEN A NAME FILES HEAVILY
Live price
Daily candles from TradingView, on their licence — no filings are marked on this one
WHY THIS NAME IS ON THE DESK
Insiders have filed to sell — before selling.
The record shows a net $7.7M sold by insiders over 180 days, 189 funds added last quarter, $10.0M in planned Form 144 sales. Every figure is a federal filing, dated the day it became public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector from the SEC's own SIC classification
UTHRCPIXMRNAREGNLLYALNYELFCITRMDGLDNAVRTXNUVL
Insider transactions
Form 4 purchases and sales (codes P and S) — grants, option exercises and preferred conversions excluded

Over the last 180 days, Amneal Pharmaceuticals, Inc. insiders sold a net $7.7M of stock across 54 Form 4 purchases and sales, with 0 insider(s) buying. Source: SEC Form 4 filings, as of 2026-09-06.

INSIDER
FILED
SHARES
VALUE
Kiely John
Director
SELL
2026-08-13
50,000.0
$882.0K
Shah Nikita
Executive Vice President
SELL
2026-08-12
146,403.0
$2.6M
Daly Jason B.
EVP, Chief Legal Officer
SELL
2026-08-12
210,000.0
$3.7M
Daly Jason B.
EVP, Chief Legal Officer
SELL
2026-08-11
6,613.0
$117.1K
Autor Deborah M.
Director
SELL
2026-05-11
34,819.0
$450.6K
54 TRANSACTIONS ON RECORD

Showing the most recent few. Create a free account to see 49 more transactions on record, the cross-source screener and CSV export. We store only your email address, and there is no password to create.

Institutional holders
13F · holdings as of the latest quarter funds have reported
BlackRock, Inc.
26,562,093.0 sh
$459.8M
TPG GP A, LLC
12,328,767.0 sh
$213.4M
VANGUARD PORTFOLIO MANAGEMENT LLC
12,137,727.0 sh
$210.1M
Rubric Capital Management LP
10,168,660.0 sh
$176.0M
VANGUARD CAPITAL MANAGEMENT LLC
7,710,126.0 sh
$133.5M
SCHEDULE 13D/G
No 5%+ ownership filings
Nobody has crossed 5% with a filing obligation. Absence is a fact here, not missing data.
Planned sales · Form 144
Filed before the sale — intent, not a trade
JOHN KIELY
FILED 2026-08-13
$879.7K
JASON DALY
FILED 2026-08-12
$3.6M
NIKITA SHAH
FILED 2026-08-12
$2.6M
BUCHI J KEVIN
FILED 2026-08-11
$2.9M
Fund concentration
N-PORT · funds ranked by how much of THEMSELVES they put in this stock — the conviction number 13F cannot show
Invesco Pharmaceuticals ETF
$8.6M POSITION · AS OF 2026-04-30
2.6%
Allspring SMID Core ETF
$1.3M POSITION · AS OF 2026-03-31
2.4%
State Street(R) SPDR(R) S&P(R) Pharmaceuticals ETF
$5.8M POSITION · AS OF 2026-03-31
1.9%
PROFUND VP PHARMACEUTICALS
$183.2K POSITION · AS OF 2026-03-31
1.8%
Columbia Small Cap Value and Inflection Fund
$13.0M POSITION · AS OF 2026-02-28
1.6%
VY(R) Columbia Small Cap Value and Inflection Portfolio
$940.2K POSITION · AS OF 2026-03-31
1.5%
SEC N-PORT, MONTHLY WITH A ~60-DAY PUBLIC LAG · FUNDS ≥ $10M · % = SHARE OF THE FUND'S OWN BOOK
Clinical pipeline
ClinicalTrials.gov · 2 registered trials, 0 still enrolling or running — a status change here is dated weeks before the press release
2
Phase 1
0 ACTIVE
What changed recently
A Randomized, Double-blind, Parallel-group, Two-arm, Multiple Dose, Multicenter, Bioequi
2026-09-03 · Recruiting → Unknown
Phase 1
TRIALS MATCHED TO THIS TICKER BY SPONSOR NAME · STUDIES RUN UNDER A SUBSIDIARY'S OWN NAME ARE NOT INCLUDED
Corporate PAC
FEC · the company-connected political action committee's own receipts and spending — committee totals only, never individual donors
Amneal Pharmaceuticals Inc. Pac
CYCLE 2026 · $30K SPENT
$53.7K
FEDERAL ELECTION COMMISSION · MATCHED BY THE PAC'S CONNECTED ORGANISATION
Fundamentals
Annual figures from XBRL filings · pick a past date to see them exactly as the market knew them then — restatements and all
2025-122024-122023-122022-12
REVENUE$3.0B$2.8B$2.4B$2.2B
GROSS PROFIT$1.1B$1.0B$820.6M$784.7M
OPERATING INCOME$394.1M$249.3M$204.4M$-94.9M
NET INCOME$72.1M$-116.9M$-84.0M$-254.8M
EPS (DILUTED)0.22-0.38-0.48-0.86
OPERATING CASH FLOW$340.0M$295.1M$345.6M$65.1M
CASH$282.0M$110.6M$91.5M$26.0M
LONG-TERM DEBT$2.6B$2.2B$2.4B$2.6B
SEC XBRL · FISCAL-YEAR PERIODS · AS KNOWN ON 2026-09-06 · NOBODY ELSE SHOWS FUNDAMENTALS AS OF A PAST DATE
W WAVEMAN

Public filings, honestly analyzed. Official US government sources in one desk — every figure carries the date it was filed, and the methodology is published, backtest included.

SEC FORM 4FORM 13F 13D/GFORM 144XBRL STOCK ACTCONTRACTSFEC CFPBNRC
PRODUCT
DeskBacktester CompaniesAccount
SUPPORT
FAQMethodology Contact
LEGAL
TermsPrivacy Accessibility
© 2026 WAVEMAN · SOURCE: SEC EDGAR & OFFICIAL GOVERNMENT DATA · NOT INVESTMENT ADVICE · CHART BY TRADINGVIEW · UPDATED 2026-09-06 ALL SYSTEMS LIVE FOR MACHINES →